LONDON – RTW Biotech Opportunities Ltd (LSE: RTW), a London Stock Exchange-listed investment company, has announced a new investment in Windward Bio’s Series A funding round, which raised $200 million. Windward Bio, a Swiss clinical-stage drug development company, is focusing on treatments for advanced immunological diseases, particularly severe respiratory conditions.
The funding will advance two undisclosed programs through Investigational New Drug (IND)-enabling studies. Windward Bio has also secured a licensing agreement for global rights to WIN378, excluding China and parts of Asia, from Kelun-Biotech and Harbour BioMed. The company is preparing to initiate a phase 2 trial for WIN378 in severe asthma, with initial results expected in 2026. Further trials in asthma and chronic obstructive pulmonary disease (COPD) are planned, targeting unmet needs in an estimated 5 million patients in the US, Europe, and Japan.
Roderick Wong, Managing Partner and CIO at RTW Investments, LP, the investment manager for RTW Biotech Opportunities Ltd, expressed enthusiasm for supporting Windward Bio’s pipeline development, particularly for WIN378, a next-generation TSLP therapy aimed at improving treatment outcomes for severe respiratory diseases.
RTW Biotech Opportunities Ltd specializes in identifying high-growth potential assets within the life sciences sector, investing in companies that develop innovative therapies and technologies. Managed by RTW Investments, LP, the fund supports businesses that have the potential to significantly improve patient outcomes.
This investment reflects the fund’s commitment to fostering advancements in life sciences, particularly in the area of treatments for complex immunological diseases. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
